Vibration Controlled Transient Elastography in Screening for Silent Liver Diseases

Objectives The objective of this study was to screen for significant hepatic fibrosis or steatosis in asymptomatic, apparently healthy subjects by using Vibration-controlled transient elastography and controlled attenuation parameter (CAP). Methods Prospectively, 433 asymptomatic apparently healthy adults were included. Fibroscan/CAP examination was performed for all of them. Subjects with liver stiffness measurement > 6 kPa or CAP > 248 dB/m were further evaluated to assess underlying chronic liver disease. Results According to fibroscan/CAP examination, subjects were classified into four subgroups: normal (119) with CAP score of 215.85 +/- 24.81 dB/m and fibrosis score of 4.47 +/- 0.81 kPa, subjects with steatosis only 133 with CAP score of 309.41 +/- 42.6 dB/m and fibrosis score of 4.74 +/- 0.82 kPa, subjects with both steatosis and fibrosis 95 with CAP score of 318.20 +/- 39.89 dB/m and fibrosis score of 7.92 +/- 2.58 kPaand subjects with fibrosis only 86 with CAP score of 213.48 +/- 22.62 dB/m and fibrosis score of 6.96 +/- 1.11 kPa. S0 was present in 205 (47.3%), S1 in 48 (10.2%), S2 in 16 (3.7%) and S3 in 168 (38.8%) of studied subjects, whereas F0-1 was present in 371 (85.7%), F2 in 44 (10.16%), F3 in 16 (3.7%) subjects and F4 in only one (0.23%) subject. Subjects with both steatosis and fibrosis showed significantly higher transaminases, triglycerides and total cholesterol levels than other subgroups. Conclusions Most asymptomatic, apparently healthy subjects (72%) have significant steatosis and fibrosis. Liver stiffness measurement and CAP might represent promising first-line noninvasive procedures to screen for silent liver diseases in the general population. Eur J Gastroenterol Hepatol 35: 1204-1210 Copyright (c) 2023 Wolters Kluwer Health, Inc. All rights reserved.